Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers

被引：13

作者：

Russano, Marco ^{[1
]}

La Cava, Giulia ^{[1
]}

Cortellini, Alessio ^{[1
]}

Citarella, Fabrizio ^{[1
]}

Galletti, Alessandro ^{[2
]}

Di Fazio, Giuseppina Rita ^{[1
]}

Santo, Valentina ^{[1
]}

Brunetti, Leonardo ^{[1
]}

Vendittelli, Alessia ^{[1
]}

Fioroni, Iacopo ^{[1
]}

Pantano, Francesco ^{[1
]}

Tonini, Giuseppe ^{[1
]}

Vincenzi, Bruno ^{[1
]}

机构：

[1] Campus Biomed Univ Rome, Dept Med Oncol, Via Alvaro Portillo 21, I-00128 Rome, Italy

[2] San Camillo Forlanini Hosp, Div Med Oncol, I-00152 Rome, Italy

来源：

CURRENT ONCOLOGY | 2023年 / 30卷 / 02期

关键词：

immunotherapy; non-small cell lung cancer; immune checkpoint inhibitors; PD-1; PD-L1; antibodies; combination strategies; biomarkers; tissue biomarkers; liquid biopsy; IMMUNE CHECKPOINT INHIBITORS; PD-L1; EXPRESSION; NSCLC PATIENTS; OPEN-LABEL; CHEMOTHERAPY CHEMO; 1ST-LINE NIVOLUMAB; ADVERSE EVENTS; CHECKMATE; 9LA; PATIENTS PTS; PHASE-III;

D O I：

10.3390/curroncol30020181

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunotherapy has revolutionized the treatment paradigm of non-small cell lung cancer and improved patients' prognosis. Immune checkpoint inhibitors have quickly become standard frontline treatment for metastatic non-oncogene addicted disease, either as a single agent or in combination strategies. However, only a few patients have long-term benefits, and most of them do not respond or develop progressive disease during treatment. Thus, the identification of reliable predictive and prognostic biomarkers remains crucial for patient selection and guiding therapeutic choices. In this review, we provide an overview of the current strategies, highlighting the main clinical challenges and novel potential biomarkers.

引用

页码：2366 / 2387

页数：22

共 50 条

[1] Biomarkers of immunotherapy for non-small cell lung cancer
Shirasawa, Masayuki
Yoshida, Tatsuya
Ohe, Yuichiro
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 54 (01) : 13 - 22
[2] Biomarkers of immunotherapy in non-small cell lung cancer
Wang, Lingling
Hu, Yue
Wang, Shengchao
Shen, Jiali
Wang, Xiaochen
ONCOLOGY LETTERS, 2020, 20 (05)
[3] Advances in efficacy prediction and monitoring of neoadjuvant immunotherapy for non-small cell lung cancer
Wang, Yunzhen
Huang, Sha
Feng, Xiangwei
Xu, Wangjue
Luo, Raojun
Zhu, Ziyi
Zeng, Qingxin
He, Zhengfu
FRONTIERS IN ONCOLOGY, 2023, 13
[4] Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives
Luo, Wenxin
Wang, Zhoufeng
Zhang, Ting
Yang, Lan
Xian, Jinghong
Li, Yalun
Li, Weimin
PRECISION CLINICAL MEDICINE, 2021, 4 (04) : 258 - 270
[5] The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancer
Pan, Yue
Fu, Yucheng
Zeng, Yue
Liu, Xiaohan
Peng, Yurong
Hu, Chunhong
Deng, Chao
Qiu, Zhenhua
Zou, Jian
Liu, Yuxuan
Wu, Fang
BIOMARKER RESEARCH, 2022, 10 (01)
[6] The use of immunotherapy in older patients with advanced non-small cell lung cancer
Tagliamento, Marco
Frelaut, Maxime
Baldini, Capucine
Naigeon, Marie
Nencioni, Alessio
Chaput, Nathalie
Besse, Benjamin
CANCER TREATMENT REVIEWS, 2022, 106
[7] Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
Wu, Xinyu
Chau, Yi Fung
Bai, Hua
Zhuang, Xiaofei
Wang, Jie
Duan, Jianchun
FRONTIERS IN ONCOLOGY, 2023, 12
[8] Biomarkers for immunotherapy resistance in non-small cell lung cancer
Rother, Catriona
John, Tom
Wong, Annie
FRONTIERS IN ONCOLOGY, 2024, 14
[9] New advances in immunotherapy for non-small cell lung cancer
Qin, Haifeng
Wang, Fang
Liu, Hui
Zeng, Zhen
Wang, Shasha
Pan, Xin
Gao, Hongjun
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2018, 10 (08): : 2234 - 2245
[10] Recent advances in therapeutic strategies for non-small cell lung cancer
Su, Po-Lan
Furuya, Naoki
Asrar, Alahmadi
Rolfo, Christian
Li, Zihai
Carbone, David P.
He, Kai
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)

← 1 2 3 4 5 →